News and Announcements
Fintech with 307,000+ Transactions in Partnership with ASX-Listed Payment Solutions Provider EML | £1.6M Raised in Seed Round
- Published September 30, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Saurus.com makes access to financial services easier, faster, and safer for unbanked or underserved people, contributing to the eradication of poverty through our social and financial inclusion programs.”
Jose Merino, CEO & Founder, Saurus.com
Executive Summary
Rewire Holding (trading as Saurus.com) is a UK-EU digital financial services solution that provides customers with tools to manage their money, make payments, and send money across borders.
Saurus.com improves the financial and social inclusion of underserved market segments such as rural communities and the Hispanic and Muslim diasporas.
Saurus.com provides users with a EUR and GBP current account and prepaid Mastercard that integrates into Google Pay, Apple Pay, SEPA Pay, SWIFT, Direct Debit, SEPA Direct Debit, Faster Payments, and 3D Secure.
Saurus.com’s business model consists of multiple revenue streams diversified across multiple client segments, including corporate clients.
Investment Highlights
- The Saurus.com app has achieved the following milestones while operating in Spain and UK:
- Serviced over 11,000 customers and enabled more than 307,000 transactions
- Issued more than 7,700 cards and over 12,000 current accounts
- Saurus.com offers a scalable range of institutional-grade services without a significant fixed cost base through its partnership with ASX-listed payment solutions infrastructure provider EML.
- The company’s founders and advisors have experience in multinational executive roles, start-ups, product development, and trade-sale exits.
- Saurus.com has already raised £1.6M from a diversified investor base.
Investment Offering
Having raised £1.6M in the seed round, the company seeks a 2021 Series A investment equity at a pre-money valuation of £119M.
This capital will accelerate growth towards a trade-sale exit or an IPO.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
